WO2007030454A3 - Mutations and polymorphisms of hdac9 - Google Patents

Mutations and polymorphisms of hdac9 Download PDF

Info

Publication number
WO2007030454A3
WO2007030454A3 PCT/US2006/034559 US2006034559W WO2007030454A3 WO 2007030454 A3 WO2007030454 A3 WO 2007030454A3 US 2006034559 W US2006034559 W US 2006034559W WO 2007030454 A3 WO2007030454 A3 WO 2007030454A3
Authority
WO
WIPO (PCT)
Prior art keywords
hdac9
mutations
mutant
polymorphisms
various aspects
Prior art date
Application number
PCT/US2006/034559
Other languages
French (fr)
Other versions
WO2007030454A2 (en
Inventor
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Kenneth Wayne Culver
Jian Zhu
Stan Lilleberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Kenneth Wayne Culver, Jian Zhu, Stan Lilleberg filed Critical Novartis Ag
Publication of WO2007030454A2 publication Critical patent/WO2007030454A2/en
Publication of WO2007030454A3 publication Critical patent/WO2007030454A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the HDAC9 gene. The invention provides new HDAC9 mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the HDAC9 mutations of the invention, expression vectors encoding the HDAC9 mutant polypeptides of the invention and organisms that express the HDAC9 mutant and polymorphic polynucleotides and/or HDAC9 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the HDAC9 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
PCT/US2006/034559 2005-09-07 2006-09-05 Mutations and polymorphisms of hdac9 WO2007030454A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71487105P 2005-09-07 2005-09-07
US60/714,871 2005-09-07

Publications (2)

Publication Number Publication Date
WO2007030454A2 WO2007030454A2 (en) 2007-03-15
WO2007030454A3 true WO2007030454A3 (en) 2007-08-02

Family

ID=37822502

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034559 WO2007030454A2 (en) 2005-09-07 2006-09-05 Mutations and polymorphisms of hdac9

Country Status (1)

Country Link
WO (1) WO2007030454A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102036955B (en) 2008-03-26 2013-03-27 诺瓦提斯公司 Hydroxamate-based inhibitors of deacetylases b
CN108685947A (en) * 2017-04-11 2018-10-23 上海尚泰生物技术有限公司 Colorectal cancer hepatic metastases primary tumor and transfer stove match model
CN110495419A (en) * 2018-05-16 2019-11-26 首都医科大学附属北京朝阳医院 A kind of mouse model of Huppert's disease extramedullary plasmacytoma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022577A2 (en) * 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022577A2 (en) * 2000-09-01 2002-03-21 Novartis Ag Hydroxamate derivatives useful as deacetylase inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MARKS P A ET AL: "HISTONE DEACETYLASE INHIBITORS: INDUCERS OF DIFFERENTIATION OR APOPTOSIS OF TRANSFORMED CELLS", JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, US, vol. 92, no. 15, 2 August 2000 (2000-08-02), pages 1210 - 1216, XP001121734, ISSN: 0027-8874 *
MONNERET C.: "histone deacetylase inhibitors", EUR. J. MEDICAL CHEMISTRY, vol. 40, 9 December 2004 (2004-12-09), pages 1 - 13, XP004708959 *
PARK J.M. ET AL.,: "no association between polymorphisms in the histone deacetylase genes and the risk of lung cancer", CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION, vol. 14, no. 7, July 2005 (2005-07-01), pages 1841 - 1843, XP002424811 *
PETRIE K. ET AL.,: "the histone deacetylase 9 gene encodes multiple protein isoforms", J. BIOL. CHEM., vol. 278, no. 18, 2 May 2003 (2003-05-02), pages 16059 - 16072, XP002424812 *
ZHOU X ET AL: "Cloning and characterization of a histone deacetylase, HDAC9", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 19, 11 September 2001 (2001-09-11), pages 10572 - 10577, XP002220349, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2007030454A2 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
WO2007016532A3 (en) Mutations and polymorphisms of hdac4
WO2006130527A3 (en) Mutations and polymorphisms of fibroblast growth factor receptor 1
WO2009132058A3 (en) Levels of bcma protein expression on b cells and use in diagnostic methods
WO2006105252A3 (en) Diagnosis of chronic pulmonary obstructive disease and monitoring of therapy using gene expression analysis of peripheral blood cells
WO2005033652A3 (en) Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
WO2006128042A3 (en) Methods of identifying mutations in nucleic acid
EP1907845A4 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
NZ600235A (en) Methods and compositions for the assessment of drug response
NZ596614A (en) Diagnosis and treatment of alzheimer's disease
WO2006110478A3 (en) Mutations and polymorphisms of epidermal growth factor receptor
EP2287340A3 (en) Method for diagnosis and treatment of a mental disease
WO2007022041A3 (en) Mutations and polymorphisms of hdac3
WO2006060393A3 (en) Biological systems analysis
EP2503338A3 (en) CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies
WO2002022879A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
MX2007008984A (en) Cancer markers and detection methods.
WO2005118403A3 (en) Methods for detecting gene expression in peripheral blood cells and uses thereof
WO2007030455A3 (en) Mutations and polymorphisms of hdac10
WO2007009101A3 (en) Tetraazaporphyrin-based compounds and their uses
SG161216A1 (en) A method of diagnosis and treatment and agents useful for same
WO2007030454A3 (en) Mutations and polymorphisms of hdac9
WO2007038073A3 (en) Mutations and polymorphisms of hdac11
WO2007058992A3 (en) Mutations and polymorphisms of hdac6
WO2007002217A3 (en) Mutations and polymorphisms of bcl-2
WO2007109183A3 (en) Mutations and polymorphisms of fms-related tyrosine kinase 1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06802978

Country of ref document: EP

Kind code of ref document: A2